20:27 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

Portola reports response data in Phase IIa of cerdulatinib in B cell malignancies

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported interim data from the Phase IIa portion of a Phase I/IIa trial evaluating oral cerdulatinib (PRT062070, PRT2070) to treat relapsed or refractory B cell malignancies. In 18 evaluable patients with...
21:17 , Jun 15, 2017 |  BC Extra  |  Clinical News

Portola reports response rates for cerdulatinib

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported interim data from a Phase IIa study of cerdulatinib ( PRT062070 ) to treat relapsed or refractory B cell malignancies, and suggested it is still deciding whether to continue development...
20:34 , Jan 6, 2017 |  BC Week In Review  |  Company News

Roivant, Portola deal

Portola granted Roivant's Dermavant Sciences subsidiary exclusive, worldwide rights to develop and commercialize cerdulatinib for topical applications outside of oncology. Dermavant said it plans to develop the dual inhibitor of spleen tyrosine kinase (SYK) and...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Clinical News

PRT062070: Phase I/II started

Portola began an open-label Phase I/II trial of PRT2070. The Phase I portion will evaluate escalating doses of PTR2070 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Aciex Therapeutics, Portola deal

Portola granted Aciex exclusive rights to co-develop Portola's portfolio of small molecule dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitors for ophthalmic indications. The portfolio includes preclinical and early stage undisclosed compounds, including...
02:08 , Feb 28, 2013 |  BC Extra  |  Company News

Portola, Aciex in ophthalmic deal

Portola Pharmaceuticals Inc. (South San Francisco, Calif.) granted Aciex Therapeutics Inc. (Westborough, Mass.) exclusive rights to co-develop Portola's portfolio of small molecule dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitors for ophthalmic indications....
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Portola preclinical data

In a mouse model of arthritis, PRT062070 suppressed inflammation. In a rat model of arthritis, PRT062070 dose-dependently inhibited inflammation and led to complete suppression of disease progression. PRT062070 is a dual inhibitor of spleen tyrosine...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Portola preclinical data

In a mouse xenograft model of B cell NHL, PRT062070 diminished progression of NHL. PRT062070 is a dual inhibitor of spleen tyrosine kinase (SYK) and JAK kinase (JAK) . Data were presented at the American...